wechat public accounts
Address: Building F2, No. 88, Kechuang 6th Street, Beijing Economic Development Zone
Tel: +86 010-56315466
Fax: +86 010-56315314
Copyright: Jacobio Pharmaceuticals Co., Ltd. Beijing ICP preparation 17065868-1
Jacobio Pharmaceuticals Appoints Hong Zhuang, Ph.D., as Senior Vice President of CMC
BEIJING, China, July 20, 2020 - Jacobio Pharmaceuticals Co., Ltd today announced the appointment of Hong Zhuang, Ph.D., as Senior Vice President of CMC.
Dr. Zhuang will lead the overall development and implementation of the CMC work. Dr. Zhuang is a highly accomplished leader and scientist with extensive experience of formulation development and manufacturing in biotechnology and pharmaceutical industries, with a deep understanding of drug discovery, development, clinical/commercial manufacturing, CMC process, and regulatory affairs.
Dr. Zhuang graduated from Peking University with bachelor and master degrees in science and received his Ph.D. degree in Pharmaceutics and Pharmaceutical Chemistry from the University of Utah in 2000. Prior to joining us, Dr. Zhuang held important positions in several multinational pharmaceuticals and biotech companies. Dr. Zhuang served as Senior Director of Drug Product Development and Manufacturing in Turning Point Therapeutics since 2018. He had been the Senior Research Scientist/Principal Research Scientist in Eli Lilly and Company for almost eleven years, where he led cross-functional team that developed more stable and improved formulation for Vancomycin which obtained approval from FDA in 2014. He had also served as Director of Formulation and Manufacturing at Newlink genetics and worked in Wyeth and Pharmacia&Upjohn which later became Pfizer.
“Dr. Zhuang’s breadth of experience and expertise, particularly in CMC will be invaluable to our current and future needs. We look forward to advancing Jacobio’s capability in CMC under his leadership and further strengthening our management team. I am very pleased to welcome Dr. Zhuang to our team in our growth.”
Jacobio Pharmaceuticals Co., Ltd. is committed to providing more products and solutions to people’s health. Our mission and vision are “For Patients” and to develop innovative drugs globally. The company’s R&D centers are located in Beijing and Boston, with a platform and expertise in developing allosteric inhibitors against protein tyrosine phosphatase, KRAS and transcriptional factors. The company is financed by several top-tier investors, including Qiming, Lilly Asia Ventures, Hillhouse and BioEngine. Please visit us at www.jacobiopharma.com.